Akouos Raises $50 Million in Series A Financing; Forms Scientific Advisory Board

Akouos is developing targeted adeno-associated viral vector (AAV)-based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and/or nerve fibers of the inner ear.